

# Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT06066957

---

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Pennsylvania
Enrollment	80 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Age is  $\geq 18$  years on the day of transplantation.
- Heart or Lung transplant recipient.
- Donor and/or Recipient CMV seropositive (defined by positive IgG) within 1 year prior to transplantation.
- Able to start oral CMV prophylaxis within 14 days (heart graft recipients) or 28 days (lung graft recipients) of transplantation.
- ... and 3 more (see full listing online)

### Exclusion (24)

- An individual who meets any of the following criteria will be excluded from participation in this study:
- Any prior solid organ transplant.
- Dual organ transplantation.
- Prior treated CMV infection.
- Unknown CMV serostatus of the donor or recipient.
- ... and 19 more (see full listing online)

## Locations (1 total)

---

Penn Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States